Floatz logo

ODEVIXIBAT

Orphan Cholestatic Liver Diseases

AlbireoSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Orphan Cholestatic Liver Diseases cohort.

Asset / SponsorPhaseRating
Linerixibat
GlaxoSmithKline
Phase 3BB
URSODEOXYCHOLIC ACID
Assistance Publique - Hôpitaux de Paris
Phase 3BB
lum001
Mirum Pharmaceuticals, Inc.
Phase 3BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3B
Tauroursodeoxycholic
Beijing Trendful Kangjian Medical Information Consulting Limited Company
Phase 3B

View all 24 →

Same molecule, other indications

ODEVIXIBAT is also rated in:

Primary Biliary CirrhosisDormant
B
Indicative ·
60 / 100
View asset →
primary biliary cholangitisDormant
B
Indicative ·
60 / 100
View asset →
progressive familial intrahepatic cholestasisDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →